Yes, add AREDS2 vitamin supplementation to patients starting anti-VEGF therapy for neovascular AMD.
Patients with neovascular (wet) AMD requiring anti-VEGF treatment should receive AREDS2 supplementation, as these therapies work through complementary mechanisms and provide additive benefits for protecting the fellow eye and potentially reducing treatment burden.
Rationale for Combined Therapy
The American Academy of Ophthalmology's Age-Related Macular Degeneration Preferred Practice Pattern explicitly addresses this scenario 1. When one eye develops neovascular AMD requiring anti-VEGF therapy, the fellow eye remains at exceptionally high risk—and AREDS2 supplements can lower the risk of progression to advanced AMD by as much as 36% over a 10-year period 1.
Key Clinical Points:
Anti-VEGF and AREDS2 are not redundant: Anti-VEGF agents (aflibercept, bevacizumab, ranibizumab) target active neovascularization through VEGF inhibition, while AREDS2 supplements work through antioxidant and anti-inflammatory pathways to slow underlying disease progression 2
Complementary benefits: Recent evidence demonstrates that Mediterranean diet adherence and AREDS2 supplementation have complementary and non-redundant effects—meaning their benefits add together rather than overlap 2
Potential treatment burden reduction: While not reaching statistical significance, a 2023 study showed patients on AREDS2 supplements for at least one year before starting anti-VEGF therapy required fewer injections over 3 years (21.89 vs 26.00 injections, P=0.083) 3. Preclinical data supports that nutritional supplements combined with anti-VEGF may mitigate CNV development more effectively than either alone 4
AREDS2 Formulation
The recommended formulation includes:
- Vitamin C (500 mg)
- Vitamin E (400 IU)
- Lutein (10 mg) and zeaxanthin (2 mg) — replacing beta-carotene
- Zinc (25-80 mg) with copper (2 mg)
- Omega-3 fatty acids
Critical Safety Considerations
Before prescribing, coordinate with the patient's primary care physician 1:
Absolute contraindications:
- Current smokers should NOT receive beta-carotene (if using original AREDS formulation) due to 28% increased relative risk of lung cancer (95% CI 1.04-1.57, P=0.02) 1
- Use AREDS2 formulation with lutein/zeaxanthin instead
Relative cautions requiring PCP review:
- Zinc at 80 mg: Increased hospitalizations for genitourinary conditions (7.5% vs 4.9%, P=0.001), including UTIs, prostatic hyperplasia, and stress incontinence 1
- Consider 25 mg zinc dose—AREDS2 showed no significant difference in AMD progression between doses 1
- Monitor for copper-deficiency anemia (copper supplementation is mandatory) 1
Clinical Algorithm
For patients starting anti-VEGF:
- Prescribe AREDS2 supplementation immediately unless contraindicated
- Assess smoking status: If current smoker, ensure lutein/zeaxanthin formulation (not beta-carotene)
- Coordinate with PCP to review medical history for genitourinary issues that might warrant lower zinc dose
- Counsel on dietary modification: Encourage Mediterranean diet pattern for additional synergistic benefit 2, 5
- Monitor fellow eye: Even with supplements, high-risk patients need periodic examination every 6-12 months to detect asymptomatic CNV early 1
The evidence strongly supports that AREDS2 supplementation should be standard care for any patient with neovascular AMD, not an optional add-on 1, 2.